Medpace Holdings, Inc. $MEDP Shares Sold by Riverbridge Partners LLC

Riverbridge Partners LLC trimmed its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.0% during the first quarter, HoldingsChannel reports. The firm owned 237,407 shares of the company’s stock after selling 35,562 shares during the period. Medpace comprises about 2.8% of Riverbridge Partners LLC’s investment portfolio, making the stock its 8th biggest holding. Riverbridge Partners LLC’s holdings in Medpace were worth $114,001,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in MEDP. AQR Capital Management LLC increased its holdings in shares of Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after purchasing an additional 324,293 shares during the last quarter. Wasatch Advisors LP boosted its stake in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Geode Capital Management LLC grew its holdings in Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after buying an additional 24,625 shares in the last quarter. Invesco Ltd. grew its holdings in Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after buying an additional 85,517 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of Medpace by 19.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after acquiring an additional 60,883 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Medpace Price Performance

Shares of MEDP stock opened at $473.48 on Wednesday. The firm has a market cap of $13.52 billion, a PE ratio of 29.76, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18. The company has a 50-day moving average of $450.81 and a two-hundred day moving average of $497.24. Medpace Holdings, Inc. has a 1-year low of $305.69 and a 1-year high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period in the previous year, the firm earned $3.67 EPS. The business’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Royal Bank Of Canada dropped their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Barclays reduced their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Finally, Robert W. Baird cut their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $467.08.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.